Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patients

Objective To identify potential serum metabolic biomarkers in colorectal cancer (CRC) patients using untargeted metabolomics and to evaluate their diagnostic and staging value. Methods Serum samples from 100 healthy controls and 100 CRC patients were analyzed by ultra-performance liquid chromatograp...

Full description

Saved in:
Bibliographic Details
Main Author: WANG Aiwei, LIU Jiaqi, LIU Xiaoyan, SUN Haidan, GUO Zhengguang, HE Chengyan, SUN Wei
Format: Article
Language:zho
Published: Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College. 2025-06-01
Series:Jichu yixue yu linchuang
Subjects:
Online Access:https://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2025-45-6-793.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849429205280882688
author WANG Aiwei, LIU Jiaqi, LIU Xiaoyan, SUN Haidan, GUO Zhengguang, HE Chengyan, SUN Wei
author_facet WANG Aiwei, LIU Jiaqi, LIU Xiaoyan, SUN Haidan, GUO Zhengguang, HE Chengyan, SUN Wei
author_sort WANG Aiwei, LIU Jiaqi, LIU Xiaoyan, SUN Haidan, GUO Zhengguang, HE Chengyan, SUN Wei
collection DOAJ
description Objective To identify potential serum metabolic biomarkers in colorectal cancer (CRC) patients using untargeted metabolomics and to evaluate their diagnostic and staging value. Methods Serum samples from 100 healthy controls and 100 CRC patients were analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). After data normalization, differential metabolites were screened using multivariate statistical analyses (PCA, OPLS-DA) and subjected to pathway enrichment analysis. Diagnostic performance was assessed via univariate and multivariate regression, while Mfuzz clustering was applied to analyze stage-related metabolites (Ⅰ-Ⅳ). Results A total of 432 metabolites were identified with 59 showing significant alterations. Starch and sucrose metabolism and glycerophospholipid metabolism pathways were significantly enriched. A three-metabolite panel (4,8- dimethylnonanoyl carnitine, 9,13-dihydroxy-4-megastigmen-3-one 9-glucoside and C17 sphingosine-1-phosphate) achieved a diagnostic AUC of 0.907, while L-Carnitine and L-Norleucine showed an AUC of 0.776 in staging analysis. Conclusions Specific serum metabolite panel exhibit high diagnostic accuracy, and dysregulated metabolic pathways are associated with CRC progression, suggesting their potential value as biomarkers.
format Article
id doaj-art-2afd131da8e842c8b75045b194e6cda7
institution Kabale University
issn 1001-6325
language zho
publishDate 2025-06-01
publisher Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.
record_format Article
series Jichu yixue yu linchuang
spelling doaj-art-2afd131da8e842c8b75045b194e6cda72025-08-20T03:28:26ZzhoInstitute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.Jichu yixue yu linchuang1001-63252025-06-0145679379910.16352/j.issn.1001-6325.2025.06.0793Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patientsWANG Aiwei, LIU Jiaqi, LIU Xiaoyan, SUN Haidan, GUO Zhengguang, HE Chengyan, SUN Wei01. Department of Pharmacology, Institute of Basic Medical Sciences CAMS, School of Basic Medicine PUMC, Beijing 100005;;2. Department of Clinical Laboratory, China-Japan Union Hospital of Jilin University, Changchun 130033, ChinaObjective To identify potential serum metabolic biomarkers in colorectal cancer (CRC) patients using untargeted metabolomics and to evaluate their diagnostic and staging value. Methods Serum samples from 100 healthy controls and 100 CRC patients were analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). After data normalization, differential metabolites were screened using multivariate statistical analyses (PCA, OPLS-DA) and subjected to pathway enrichment analysis. Diagnostic performance was assessed via univariate and multivariate regression, while Mfuzz clustering was applied to analyze stage-related metabolites (Ⅰ-Ⅳ). Results A total of 432 metabolites were identified with 59 showing significant alterations. Starch and sucrose metabolism and glycerophospholipid metabolism pathways were significantly enriched. A three-metabolite panel (4,8- dimethylnonanoyl carnitine, 9,13-dihydroxy-4-megastigmen-3-one 9-glucoside and C17 sphingosine-1-phosphate) achieved a diagnostic AUC of 0.907, while L-Carnitine and L-Norleucine showed an AUC of 0.776 in staging analysis. Conclusions Specific serum metabolite panel exhibit high diagnostic accuracy, and dysregulated metabolic pathways are associated with CRC progression, suggesting their potential value as biomarkers.https://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2025-45-6-793.pdfcolorectal cancer|untargeted metabolomics|uplc-ms|serum biomarkers
spellingShingle WANG Aiwei, LIU Jiaqi, LIU Xiaoyan, SUN Haidan, GUO Zhengguang, HE Chengyan, SUN Wei
Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patients
Jichu yixue yu linchuang
colorectal cancer|untargeted metabolomics|uplc-ms|serum biomarkers
title Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patients
title_full Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patients
title_fullStr Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patients
title_full_unstemmed Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patients
title_short Non-targeted metabolomics screening for serum biomarkers in colorectal cancer patients
title_sort non targeted metabolomics screening for serum biomarkers in colorectal cancer patients
topic colorectal cancer|untargeted metabolomics|uplc-ms|serum biomarkers
url https://journal11.magtechjournal.com/Jwk_jcyxylc/fileup/1001-6325/PDF/1001-6325-2025-45-6-793.pdf
work_keys_str_mv AT wangaiweiliujiaqiliuxiaoyansunhaidanguozhengguanghechengyansunwei nontargetedmetabolomicsscreeningforserumbiomarkersincolorectalcancerpatients